Abstract: Disclosed herein are methods of forming compounds and exemplary stable compounds in the nature of a conjugated compound at refrigerated or room temperature, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).
Type:
Grant
Filed:
February 26, 2021
Date of Patent:
July 4, 2023
Assignee:
KBIO HOLDINGS LIMITED
Inventors:
Steven D. Hume, Leigh Burden, Joshua Morton, Greg Pogue, Barry Bratcher, Hugh A. Haydon, Carrie A. Simpson, Nick Partain, Youngjun Oh, John W. Shepherd, Michael H. Pauly
Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
Type:
Grant
Filed:
October 18, 2021
Date of Patent:
June 20, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
Abstract: The present application relates to a lipopeptide for potently inhibiting HIV, a derivative thereof, or a pharmaceutical composition thereof, and use thereof. The lipopeptide is the following a) or b): a) a lipopeptide formed by linking a polypeptide having an antiviral activity to a lipophilic compound linked to the carboxyl-terminus of the polypeptide; or b) a lipopeptide formed by linking a polypeptide having an antiviral activity to a terminal protecting group and a lipophilic compound linked to the carboxyl-terminus of the polypeptide, wherein the terminal protecting group is an amino-terminal protecting group and/or a carboxyl-terminal protecting group, the polypeptide has a sequence of 28 amino acid residues, corresponding to amino acids at positions of 127-154 of the sequence of gp41 from HIV-1 strain HXB2.
Type:
Grant
Filed:
April 18, 2017
Date of Patent:
June 20, 2023
Assignees:
Shanxi Kangbao Biological Product Co., Ltd., Institute of Pathogen Biology, Chinese Academy of Medical Sciences
Abstract: The present invention provides vaccine or immunogenic compositions comprising novel antigens derived from the equine strain of influenza H3N8. These proteins and specific immunogenic domains are effective as primary universal influenza antigens. The disclosed vaccines or immunogenic compositions are highly effective in inducing HA specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes. In some embodiments, the vaccine is cross-protective against two or more (e.g., 2, 3, 4, 5, or 6) subtypes of influenza with or without the use of an adjuvant.
Type:
Grant
Filed:
May 1, 2019
Date of Patent:
June 13, 2023
Assignee:
Iowa State University Research Foundation, Inc.
Inventors:
David Verhoeven, Jessie Dorothy Trujillo, Brett Sponseller
Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
Type:
Grant
Filed:
November 27, 2019
Date of Patent:
May 16, 2023
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
Abstract: The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.
Abstract: Immunogen enhancers for admixture with an antigen of interest are described herein. The enhancers generally comprise a steroid acid and/or a steroid acid-peptide conjugate in an amount sufficient to improve or modify the adaptive immune response to antigens admixed therewith. In embodiments, the steroid acid may be a bile acid and the peptide may comprise one or more functional domains, such as a nuclear localization signal, which may facilitate antigen-presentation and/or antigen cross-presentation, thereby triggering improved cellular immunity, or improved cellular and humoral immunity, against the antigen.
Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
Type:
Grant
Filed:
October 27, 2021
Date of Patent:
March 7, 2023
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.
Type:
Grant
Filed:
December 1, 2017
Date of Patent:
March 7, 2023
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomv and Biologv
Abstract: The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise antigens, such as peptide-MHC (pMHC) class I molecules, and specific combinations of cytokines and co-stimulatory molecules to allow effective expansion and functional stimulation of specific T cells.
Type:
Grant
Filed:
December 20, 2017
Date of Patent:
February 28, 2023
Assignee:
Danmarks Tekniskte Universitet
Inventors:
Sine Reker Hadrup, Vibeke Mindahl Rafa, Søren Nyboe Jakobsen
Abstract: Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
February 28, 2023
Assignee:
Baylor College of Medicine
Inventors:
Carlos A. Ramos, Cliona M. Rooney, Neeharika Narala
Abstract: The present invention relates to T cells, in particular a non-activated T cell, comprising an exogenous nucleic acid encoding a T cell Receptor (TCR) specific for a virus. An embodiment of the invention is directed to a non-activated (resting) T cell expressing Hepatitis B virus (HBV) envelope s183-191 TCR capable of inhibiting viral replication and which shows reduced expression of perforins and/or granzymes in response to stimulation as compared to an activated T cell expressing the said TCR. Also encompassed are methods for producing such cells, compositions, pharmaceutical compositions and kits comprising such cells and medical uses thereof.
Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant hemagglutinin (HA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant HA polypeptides.
Type:
Grant
Filed:
March 27, 2019
Date of Patent:
February 14, 2023
Assignee:
Sanofi Pasteur Inc.
Inventors:
Tod Strugnell, Eliud Oloo, Raymond Oomen, Thorsten Vogel, Harold Kleanthous
Abstract: An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
February 7, 2023
Assignees:
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL, SCIENCE AND TECHNOLOGY, UNIVERSITY OF TOYAMA
Abstract: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
January 24, 2023
Assignee:
Regeneran Pharmaceuticals, Inc.
Inventors:
Kevin A. Bray, Frank Delfino, Matthew C. Franklin, Elena S. Garnova, Jessica Kirshner, Douglas MacDonald, William Olson, Gavin Thurston
Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
Abstract: Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound demonstrating enhanced stability, which in some embodiments comprises a protein and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for unrefrigerated storage for longer time periods than previous approaches, thus making feasible access to such products over a global supply chain.
Type:
Grant
Filed:
December 10, 2019
Date of Patent:
December 20, 2022
Assignee:
KBIO HOLDINGS LIMITED
Inventors:
Leigh Burden, Steven D. Hume, Joshua Morton, Greg Pogue, Barry Bratcher, Hugh A. Haydon, Carrie A. Simpson, Nick Partain, John W. Shepherd